Section Arrow
Quote
SUPN.NASDAQ
- Supernus Pharmaceuticals
Quotes are at least 15-min delayed:2026/04/03 12:36 EDT
Regular Hours
Last
 50.48
-0.96 (-1.87%)
Day High 
51.365 
Prev. Close
51.44 
1-M High
56.49 
Volume 
472.50K 
Bid
36.63
Ask
50.48
Day Low
50.08 
Open
50.49 
1-M Low
46.83 
Market Cap 
2.96B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 49.81 
20-SMA 50.9 
50-SMA 51.03 
52-W High 59.68 
52-W Low 29.16 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.68/1.09
Enterprise Value
2.99B
Balance Sheet
Book Value Per Share
18.44
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
718.95M
Operating Revenue Per Share
10.63
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health19.14-0.7-3.53%38.88PE
BCRXBioCryst Pharmaceuticals9.02-0.36-3.84%7.79PE
CGCCanopy Growth Corp1+0.0256+2.63%-- 
VTRSViatris13.44-0.19-1.39%-- 
ESPREsperion Therapeutics2.61------ 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.